Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Iprindole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 known ✓ | P50406 | 2/20 | 0.97 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.97 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.97 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.97 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.97 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.97 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.97 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.97 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.97 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.97 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.97 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.97 |
| ▸ | AVPR2 known ✓ | P30518 | 1/20 | 0.97 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.97 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.97 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.97 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.97 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iprindole SCHEMBL49509 | 0.99 | HTR6 (1.00) | HTR6CHRM2HTR1ACHRM5ADRA2A | |
| SCHEMBL11891460 | 0.99 | HTR6 (1.00) | HTR6CHRM2HTR1ACHRM5ADRA2A | |
| Iprindole SCHEMBL29407410 | 0.99 | HTR6 (1.00) | HTR6CHRM2HTR1ACHRM5ADRA2A | |
| SCHEMBL25818911 | 0.91 | HTR6 (0.85) | HTR6CHRM2HTR1ACHRM5ADRA2A | |
| SCHEMBL11530278 | 0.85 | CHRM2 (0.76) | HTR6CHRM2HTR1ACHRM5ADRA2A | |
| SCHEMBL11531885 | 0.83 | CHRM2 (0.72) | HTR6CHRM2HTR1ACHRM5ADRA2A | |
| SCHEMBL10737829 | 0.81 | HTR6 (0.70) | HTR6CHRM2HTR1ACHRM5ADRA2A | |
| SCHEMBL10738401 | 0.81 | HTR6 (0.70) | HTR6CHRM2HTR1ACHRM5ADRA2A | |
| SCHEMBL10735873 | 0.81 | HRH3 (0.70) | HTR6CHRM2HTR1ACHRM5ADRA2A | |
| Melitracen SCHEMBL10002403 | 0.81 | SLC6A2 (0.67) | HTR6CHRM2HTR1ACHRM5ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| CN-106397305-A | Synthesis method of iprindole as iprindole hydrochloride drug intermediate | 厦门安普顿信息科技有限公司 | 2017-02-15 | — | — | CN | disclosed |
| CN-106397305-A | Synthesis method of iprindole as iprindole hydrochloride drug intermediate | 厦门安普顿信息科技有限公司 | 2017-02-15 | — | — | CN | disclosed |
| CN-105566203-A | Method for synthesizing iprindole hydrochloride pharmaceutical intermediate iprindole | CHENGDU CARDIFF SCIENCE AND TECH CO LTD | 2016-05-11 | — | — | CN | disclosed |
| CN-105566203-A | Method for synthesizing iprindole hydrochloride pharmaceutical intermediate iprindole | CHENGDU CARDIFF SCIENCE AND TECH CO LTD | 2016-05-11 | — | — | CN | disclosed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | disclosed |
| EP-1534239-A2 | PREPARATION OF SUBMICRON SIZED PARTICLES WITH POLYMORPH CONTROL AND NEW POLYMORPH OF ITRACONAZOLE | BAXTER INTERNATIONAL INC. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004054500-A2 | PREPARATION OF SUBMICRON SIZED PARTICLES WITH POLYMORPH CONTROL AND NEW POLYMORPH OF ITRACONAZOLE | BAXTER INTERNATIONAL INC. (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20030096013-A1 | Preparation of submicron sized particles with polymorph control | BAXTER INTERNATIONAL INC. | 2003-05-22 | — | — | US | disclosed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | disclosed |